Sequana Medical NV (EBR:SEQUA)
Belgium flag Belgium · Delayed Price · Currency is EUR
1.074
+0.012 (1.13%)
Aug 22, 2025, 5:35 PM CET
1.13%
Market Cap62.86M
Revenue (ttm)105.50K
Net Income (ttm)-44.65M
Shares Out58.53M
EPS (ttm)-1.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume239,191
Average Volume477,536
Open1.054
Previous Close1.062
Day's Range1.020 - 1.074
52-Week Range0.471 - 4.390
Beta0.01
RSI36.99
Earnings DateSep 8, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium. [Read more]

Sector Healthcare
Founded 2006
Employees 48
Stock Exchange Euronext Brussels
Ticker Symbol SEQUA
Full Company Profile

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.

Financial Statements